贝达药业(300558) - 2024 Q2 - 季度业绩预告

Financial Performance - The estimated net profit for the first half of 2024 is projected to be between 20,762.88 million RMB and 23,729.01 million RMB, representing a year-on-year growth of 40.00% to 60.00% compared to 14,830.63 million RMB in the same period last year [4]. - The net profit after deducting non-recurring gains and losses is expected to be between 21,214.78 million RMB and 22,982.67 million RMB, reflecting a significant increase of 140.00% to 160.00% from 8,839.49 million RMB in the previous year [4]. - The company's main business revenue is steadily increasing, and operational efficiency is further improving, leading to stable growth in performance [6]. Product and Market Strategy - The company has five listed drugs, four of which are included in the national medical insurance catalog, contributing to the revenue growth [5]. - The company is actively conducting post-marketing clinical research to expand indications and enhance product differentiation advantages [5]. - Continuous efforts are being made to strengthen market promotion and improve drug market share across hospitals and pharmacies nationwide [6]. Caution and Disclosure - The financial data presented is preliminary and has not been audited by the accounting firm, with detailed financial information to be disclosed in the 2024 semi-annual report [5]. - Investors are advised to be cautious and aware of investment risks based on the preliminary nature of the performance forecast [6].